Arcturus Therapeutics Holdings annual shareholders’ equity
2018
2019
2020
2021
2022
2023
2024
2025
Arcturus Therapeutics Holdings Shareholders’ Equity Growth & History (ARCT)
Arcturus Therapeutics Holdings's shareholders’ equity was $214.0M for fiscal 2025.
View full Arcturus Therapeutics Holdings company overviewArcturus Therapeutics Holdings annual shareholders’ equity history
| Fiscal year | Period ended | Shareholders’ equity | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $214.0M | −$27.0M | −11.20% |
| 2024 | 2024-12-31 | $241.0M | −$37.5M | −13.48% |
| 2023 | 2023-12-31 | $278.5M | $8.2M | +3.03% |
| 2022 | 2022-12-31 | $270.3M | $42.1M | +18.45% |
| 2021 | 2021-12-31 | $228.2M | −$168.3M | −42.45% |
| 2020 | 2020-12-31 | $396.6M | $370.8M | +1437.50% |
| 2019 | 2019-12-31 | $25.8M | $12.2M | +89.06% |
| 2018 | 2018-12-31 | $13.6M | — | — |
Arcturus Therapeutics Holdings quarterly shareholders’ equity
Q4.18
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shareholders’ equity | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $171.8M | −$59.2M | −25.64% |
| Q1 2026 | 2026-03-31 | $191.4M | −$42.4M | −18.14% |
| Q4 2025 | 2025-12-31 | $214.0M | −$27.0M | −11.20% |
| Q3 2025 | 2025-09-30 | $224.6M | −$37.3M | −14.25% |
| Q2 2025 | 2025-06-30 | $231.1M | −$27.5M | −10.65% |
| Q1 2025 | 2025-03-31 | $233.8M | −$30.2M | −11.45% |
| Q4 2024 | 2024-12-31 | $241.0M | −$37.5M | −13.48% |
| Q3 2024 | 2024-09-30 | $261.9M | −$18.2M | −6.50% |
| Q2 2024 | 2024-06-30 | $258.6M | −$26.6M | −9.32% |
| Q1 2024 | 2024-03-31 | $264.0M | −$65.3M | −19.83% |
| Q4 2023 | 2023-12-31 | $278.5M | $8.2M | +3.03% |
| Q3 2023 | 2023-09-30 | $280.1M | $134.4M | +92.26% |
| Q2 2023 | 2023-06-30 | $285.2M | $114.5M | +67.05% |
| Q1 2023 | 2023-03-31 | $329.2M | $144.5M | +78.21% |
| Q4 2022 | 2022-12-31 | $270.3M | $42.1M | +18.45% |
| Q3 2022 | 2022-09-30 | $145.7M | −$113.5M | −43.79% |
| Q2 2022 | 2022-06-30 | $170.7M | −$134.9M | −44.15% |
| Q1 2022 | 2022-03-31 | $184.7M | −$167.9M | −47.60% |
| Q4 2021 | 2021-12-31 | $228.2M | −$168.3M | −42.45% |
| Q3 2021 | 2021-09-30 | $259.1M | −$2.5M | −0.96% |
| Q2 2021 | 2021-06-30 | $305.6M | $212.2M | +227.17% |
| Q1 2021 | 2021-03-31 | $352.6M | $335.6M | +1976.36% |
| Q4 2020 | 2020-12-31 | $396.6M | $370.8M | +1437.50% |
| Q3 2020 | 2020-09-30 | $261.6M | $225.7M | +628.88% |
| Q2 2020 | 2020-06-30 | $93.4M | $71.8M | +332.15% |
| Q1 2020 | 2020-03-31 | $17.0M | — | — |
| Q4 2019 | 2019-12-31 | $25.8M | $12.2M | +89.06% |
| Q3 2019 | 2019-09-30 | $35.9M | — | — |
| Q2 2019 | 2019-06-30 | $21.6M | — | — |
| Q4 2018 | 2018-12-31 | $13.6M | — | — |
Arcturus Therapeutics Holdings shareholders’ equity trends
Over the last five fiscal years, Arcturus Therapeutics Holdings's shareholders’ equity decreased from $396.6M to $214.0M, a change of −$182.6M. The latest reported quarter, Q2 2026, shows $171.8M.
About the metric
What shareholders’ equity means
Shareholders’ equity is the residual accounting value attributable to shareholders after liabilities are subtracted from assets. It can change through earnings, losses, dividends, share issuance, repurchases, and other comprehensive income.
Calculation and source
SEC-reported shareholders’ equity
TickerStat standardizes stockholders’ or shareholders’ equity reported in company SEC filings at each balance-sheet date. Negative equity is retained because it can be economically meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Arcturus Therapeutics Holdings source filings ↗